Kristin Wallace1, Allan DeToma2, David N Lewin3, Shaoli Sun3, Don Rockey4, Carolyn D Britten5, Jennifer D Wu6, Aissatou Ba7, Anthony J Alberg2, Elizabeth G Hill2. 1. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. Electronic address: wallack@musc.edu. 2. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. 3. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC. 4. Department of Medicine, Medical University of South Carolina, Charleston, SC. 5. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC. 6. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC. 7. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.
Abstract
INTRODUCTION: African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC). Recent reports have indicated that the racial difference in survival has worsened over time, especially among younger patients. To better characterize this association, we used population-based Surveillance, Epidemiology, and End Results registry data to evaluate the effect of race on stage IV CRC survival in patients aged < 50 and ≥ 50 years. PATIENTS AND METHODS: The population included 16,782 patients diagnosed with stage IV colon and rectal adenocarcinoma from January 1, 2004 and December 31, 2011. Cox proportional hazards regression was used to evaluate the association between race and other prognostic factors and the risk of death in each age group. RESULTS: Younger AAs compared with EAs had a greater prevalence of proximal CRC at diagnosis, a factor associated with a significantly greater risk of death in both races. Among patients < 50 years old, AAs had a greater risk of death compared with EAs (hazard ratio, 1.35; 95% confidence interval, 1.20-1.51), which was attenuated in patients ≥ 50 years of age (hazard ratio, 1.10; 95% confidence interval, 1.04-1.16); P for interaction = .01. CONCLUSION: The results revealed poor overall survival for AAs compared with EAs, especially for those < 50 years of age. The greater prevalence of proximal CRC at diagnosis among younger AAs (vs. EAs) might contribute to the racial difference in survival. Future studies are needed to understand how the colonic location affects the efficacy of treatment regimens.
INTRODUCTION: African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC). Recent reports have indicated that the racial difference in survival has worsened over time, especially among younger patients. To better characterize this association, we used population-based Surveillance, Epidemiology, and End Results registry data to evaluate the effect of race on stage IV CRC survival in patients aged < 50 and ≥ 50 years. PATIENTS AND METHODS: The population included 16,782 patients diagnosed with stage IV colon and rectal adenocarcinoma from January 1, 2004 and December 31, 2011. Cox proportional hazards regression was used to evaluate the association between race and other prognostic factors and the risk of death in each age group. RESULTS: Younger AAs compared with EAs had a greater prevalence of proximal CRC at diagnosis, a factor associated with a significantly greater risk of death in both races. Among patients < 50 years old, AAs had a greater risk of death compared with EAs (hazard ratio, 1.35; 95% confidence interval, 1.20-1.51), which was attenuated in patients ≥ 50 years of age (hazard ratio, 1.10; 95% confidence interval, 1.04-1.16); P for interaction = .01. CONCLUSION: The results revealed poor overall survival for AAs compared with EAs, especially for those < 50 years of age. The greater prevalence of proximal CRC at diagnosis among younger AAs (vs. EAs) might contribute to the racial difference in survival. Future studies are needed to understand how the colonic location affects the efficacy of treatment regimens.
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Amir Qaseem; Thomas D Denberg; Robert H Hopkins; Linda L Humphrey; Joel Levine; Donna E Sweet; Paul Shekelle Journal: Ann Intern Med Date: 2012-03-06 Impact factor: 25.391
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Neil Murphy; Howard D Strickler; Frank Z Stanczyk; Xiaonan Xue; Sylvia Wassertheil-Smoller; Thomas E Rohan; Gloria Y F Ho; Garnet L Anderson; John D Potter; Marc J Gunter Journal: J Natl Cancer Inst Date: 2015-08-01 Impact factor: 13.506
Authors: Nestor F Esnaola; Andrew K Stewart; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas Journal: Ann Surg Oncol Date: 2008-08-19 Impact factor: 5.344
Authors: Kristin Wallace; Katherine R Sterba; Elena Gore; David N Lewin; Marvella E Ford; Melanie B Thomas; Anthony J Alberg Journal: Clin Colorectal Cancer Date: 2013-12 Impact factor: 4.481
Authors: John M Carethers; Bhavya Murali; Bing Yang; Ryan T Doctolero; Akihiro Tajima; Ranor Basa; E Julieta Smith; Monte Lee; Ryan Janke; Tina Ngo; Ruth Tejada; Ming Ji; Matthew Kinseth; Betty L Cabrera; Katsumi Miyai; Temitope O Keku; Christopher F Martin; Joseph A Galanko; Robert S Sandler; Kathleen L McGuire Journal: PLoS One Date: 2014-06-23 Impact factor: 3.240
Authors: Kristin Wallace; Hong Li; J Grant Brazeal; David N Lewin; Shaoli Sun; Aissatou Ba; Chrystal M Paulos; Saleh Rachidi; Zihai Li; Alexander V Alekseyenko Journal: Cancer Epidemiol Date: 2020-06-07 Impact factor: 2.984
Authors: Alem A Belachew; Monica E Reyes; Yuanqing Ye; Gottumukkala S Raju; M Alma Rodriguez; Xifeng Wu; Michelle A T Hildebrandt Journal: Qual Life Res Date: 2020-07-03 Impact factor: 4.147
Authors: Kristin Wallace; David N Lewin; Shaoli Sun; Clayton M Spiceland; Don C Rockey; Alexander V Alekseyenko; Jennifer D Wu; John A Baron; Anthony J Alberg; Elizabeth G Hill Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254
Authors: Kristin Wallace; Georges J Nahhas; Christine Bookhout; David N Lewin; Chrystal M Paulos; Nana Nikolaishvili-Feinberg; Stephanie M Cohen; Silvia Guglietta; Ali Bakhtiari; E Ramsay Camp; Elizabeth G Hill; John A Baron; Jennifer D Wu; Alexander V Alekseyenko Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244
Authors: Thomas Curran; Zequn Sun; Brielle Gerry; Victoria J Findlay; Kristin Wallace; Zihai Li; Chrystal Paulos; Marvella Ford; Mark P Rubinstein; Dongjun Chung; E Ramsay Camp Journal: Cancer Med Date: 2021-02-09 Impact factor: 4.711